This assumption is supported by a prior outcome trial and observational data 20,41
Then there is the question of whether the drug would stop working for alcohol cravings when people stop taking it, the way it does for weight loss
FRIDAY, May 31, 2024 (HealthDay News) -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from cardiovascular causes, according to a study published online May 24 in the New England Journal of Medicine to coincide with the annual European Renal Association Congress, held from May 23 to 26 in Stockholm
In the SUSTAIN clinical trial program evaluating semaglutide for type 2 diabetes, gastrointestinal adverse events were reported by approximately 30-50% of participants, with the incidence varying by dose
You should stop using Ozempic 2 months before you plan to become pregnant are breastfeeding or plan to breastfeed